论文部分内容阅读
作者们对25例原发性前列腺癌的病人经会阴部钻针吸取前列腺癌组织,得0.05～0.20克标本,选择Methyltrienolone作配体(Ligand),用DCC法测癌组织胞浆液中结合量,再以Scalchard作图计算。使用此合成雄激素,因为它易与细胞内受体结合,而不与污染来自血浆的睾丸酮结合球蛋白的结合,同时具有代谢慢,在0℃保温24小时可与大约70%的受体结合内源性类固醇交换的优点。测定结果证明20例肿瘤可测到Methyltrienolone受体;其中一例在内分泌治疗开始之前死亡,另一例高分化癌未接受任何内分泌治疗,15例对去势、雌激
The authors of 25 patients with primary prostate cancer were treated with perineal drilling needles to draw prostate cancer tissue, and 0.05-0.20 g samples were obtained. Methyltrienolone was selected as a ligand and the amount of cytoplasm in the cytoplasm was measured by DCC. , and then calculated by Scalchard. This synthetic androgens is used because it binds easily to intracellular receptors and does not contaminate the binding of testosterone-binding globulin from plasma. It also has a slow metabolism, and it binds to about 70% of receptors when incubated at 0°C for 24 hours. The advantages of endogenous steroid exchange. The results showed that 20 cases of tumors could detect Methyltrienolone receptors; one case died prior to the start of endocrine therapy, another well-differentiated carcinoma did not receive any endocrine therapy, and 15 cases had castration and estrogen stimulation.